Trade | Association for Accessible Medicines
GRx+Biosims - No-cost FDA workshop limited to first 100 who sign up. Act now!

Trade

AAM's Karin Hessler Provides an Inside Look at the GRx+Biosims 2019 Legal Track

Karin Hessler, Assistant General Counsel at the Association for Accessible Medicines, urges attendees to add their voice to the discussion at the one essential generic and biosimilar conference of the year: GRx+Biosims 2019, November 4—6 in Bethesda, MD.

The conference legal track:

The House Has Spoken – It’s Time to Fix USMCA’s Pharmaceutical Provisions

In a letter given to U.S. Trade Representative Robert Lighthizer today, 102 members of the House of Representatives expressed strong concern that the pharmaceutical provisions included in the U.S.-Mexico-Canada Agreement (USMCA) – NAFTA 2.0 – could increase prices for medicines in the United States, while limiting the ability of Congress to lessen pharmaceutical monopoly rights.

Highlights from the NAFTA 2.0 Congressional Briefing: The May 10 Amendments

On May 10, 2019, the Association for Accessible Medicines (AAM) hosted a briefing for congressional staff and other stakeholders on the twelfth anniversary of the May 10 Agreement, the bipartisan agreement to reopen the Colombia, Panama, Peru and South Korea trade agreements to address labor, environment and access to medicines issues.

The USMCA Will Keep Drug Prices Out of Reach for Patients, But Congress Can Fix It

The USMCA Creates New Barriers, Delays Patient Access to Affordable Medicines — Especially Biosimilars.

The Agreement would delay U.S. patient access to competition from low-cost, high-quality generic and biosimilar medicines, and fails to include strong incentives for their approval and uptake. 

Read Full Brief

 

NAFTA 2.0: Obstacles to More Affordable Medicines

NAFTA 2.0 (USMCA) will keep drug prices out of reach for American patients.

Patients in the U.S. are already confronted by the world’s longest climb to affordable biosimilar medicines. NAFTA 2.0 (USMCA) will eliminate easier routes and keeps drug prices out of reach for American patients.

The U.S.-Mexico-Canada Agreement (USMCA), the update to the North America Free Trade Agreement (NAFTA), contains provisions that will: 

Jonathan Kimball Joins AAM as Vice President, Trade and International Affairs

WASHINGTON DC (February 25, 2019) – Jonathan Kimball joins the Association for Accessible Medicines as Vice President, Trade and International Affairs, effective today.

“Jonathan will bring a wealth of government and industry advocacy experience to an area of increasing importance to AAM and our members,” said Jeff Francer, AAM’s Senior Vice President and General Counsel. “We are extremely lucky to have him on our team.”

Subscribe to Trade

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.